Correspondence
In Brief Velez et al. report the crystal structure of the calpain-5 protease core (CAPN5-PC). Sequence-and structure-based phylogenetic analysis reveals that CAPN5-PC contains three elongated loops compared to classical calpains. One loop contains a hyperactivating mutation that causes neovascular inflammatory vitreoretinopathy, revealing a function in this region for regulating proteolytic activity.
INTRODUCTION
Aberrant elevation of intracellular calcium levels leads to dysregulation of calpain-mediated proteolytic events, which can result in necrotic cell death and neuroinflammation (Artal-Sanz and Tavernarakis, 2005; Syntichaki et al., 2002) . Excess calpain activity is implicated in a wide range of human neuroinflammatory diseases, including Parkinson's disease, Alzheimer's disease, stroke, multiple sclerosis, and retinal degeneration (Hoffmann et al., 2013; Hong et al., 1994; Samantaray et al., 2008; Shields et al., 1999; Trinchese et al., 2008) . The only known inherited disease characterized by calpain hyperactivity is neovascular inflammatory vitreoretinopathy (NIV, OMIM: 193235) , a dominantly inherited, severe inflammatory retinal disease caused by mutations in CAPN5 (Mahajan et al., 2012) . The CAPN5 gene encodes for the Ca 2+ -activated cysteine protease, calpain-5 (CAPN5). Fifteen mammalian calpains comprise a family of Ca 2+ -dependent cysteine proteases that mediate limited proteolysis in the cell. These tightly regulated reactions make irreversible changes in their protein targets, facilitating a wide range of cellular processes, such as cell morphogenesis, cell signaling, membrane repair, and apoptosis (Campbell and Davies, 2012; Ono and Sorimachi, 2012; Singh et al., 2014) .
Evolutionary gene duplication events have generated 15 human genes that encode a conserved calpain-like protease core domain. Calpains can be broadly divided into two subfamilies based on their domain architecture (Ono and Sorimachi, 2012) . The ''classical'' calpains (e.g., CAPN1 and CAPN2) are comprised of a large and small subunit. The large subunit houses the protease core domain formed by two globular subdomains (PC1 and PC2) separated by a flexible linker, a calpain b sandwich domain (CBSW; DIII), and a Ca 2+ -binding penta-EF (PEF) hand domain ( Figure 1A) . The PEF-hand of the large subunit, PEF(L), serves as a dimerization module with the small subunit comprised of a glycine-rich region followed by a C-terminal PEF-hand, PEF(S). The PEF-hands are postulated to regulate enzymatic activity and form interactions with the endogenous calpain-inhibitor, calpastatin (CAST) (Campbell and Davies, 2012; Hanna et al., 2008) . In contrast, the ''non-classical'' Capn5 and Capn6 genes were originally identified as orthologs of the tra-3 gene, a C. elegans gene encoding for the sex-determination factor TRA-3 (Matena et al., 1998) . CAPN5 (also termed hTRA-3) and CAPN6 (a catalytically inactive calpain) are the most distant paralogs of the calpain family: they lack the PEF-hand domain and instead contain a C2 domain that is structurally similar to the CBSW domain ( Figure 1B ) (Rizo and S€ udhof, 1998) . CAPN5 is broadly expressed, but displays high expression levels in select tissues, including the central nervous system (CNS), retina, and gastrointestinal tract (Dear et al., 1997; Dear and Boehm, 1999; Schaefer et al., 2016; Singh et al., 2014) . Despite these differences, the CAPN5 protease core (termed CAPN5-PC) has conserved Ca 2+ -binding sites and is predicted to undergo activation in the presence of Ca 2+ (Gakhar et al., 2016) . It is unclear, however, what structural features distinguish CAPN5-PC from classical calpain core domains. Distinct structural features, such as surface-exposed flexible loops, may alter the enzyme's activity independent of its Ca 2+ requirements or non-catalytic domains.
Studying human mutations is an effective way to probe the mechanisms regulating enzyme activity. Known CAPN5 mutations increase activity and cause NIV, while most other disease-causing calpain mutations result in a loss-of-function (e.g., CAPN1 mutations result in spastic paraplegia and CAPN3 mutations cause limb girdle muscular dystrophy type 2A) (Potz et al., 2016) . Prior to blindness around the 5 th decade of life, NIV progresses through a series of predictable pathological disease stages characterized by synaptic signaling defects (loss of b-wave on electroretinogram), inflammatory cell infiltration, neovascularization, and intra- The unrooted tree is represented with clades colored according to their representative nomenclature: classical (green), non-classical (gray), and CAPN5-like (red). The positions of human CAPN5 and rat CAPN1 are denoted by black dots for reference. (E) The unrooted CAPN5 sub-tree is represented with clades colored by related organisms. Bootstrap values are projected onto the tree topology. ocular fibrosis. These 5 stages mimic common eye diseases that together account for a significant fraction of visual morbidity and blindness: uveitis, retinitis pigmentosa, proliferative diabetic retinopathy, and proliferative vitreoretinopathy (Velez et al., 2017) . Thus, understanding how CAPN5 mutations lead to disease may provide insight into the mechanisms underlying common causes of blindness. To date, most NIV-causing mutations are located in the PC2 domain on gating loops near the active site. Three of the mutations are located on a flexible regulatory loop (termed the G1 gating loop) believed to gate access of substrates into the active site (Bassuk et al., 2015) . NIV mutations are predicted to disrupt this regulatory function, leaving the active site always available to substrates and relieving the Ca 2+ requirement for activation. Thus, NIV mutations are predicted to hyperactivate the protease. We recently identified a de novo CAPN5 mutation (p.R289W) in a pediatric patient with early-onset severe vitreoretinopathy, optic neuritis, and hearing loss. This mutation, which is located on a different loop, displayed higher enzymatic activity than the previously identified mutations, suggesting a correlation between the level of protease hyperactivity and disease severity (Velez et al., 2018) .
The high levels of CAPN5 in the CNS, its genetic association with retinal disease, and successful oral delivery of calpain inhibitors to the retina imply CAPN5 inhibition is a promising strategy for NIV therapy (Oka et al., 2007) . However, there are no highresolution structures of CAPN5 to guide structure-based inhibitor design. There have been numerous efforts to inhibit calpains in disease, including Alzheimer disease, multiple sclerosis, spinal muscular atrophy, myocardial infarction, and cerebrovascular disease (Ono et al., 2016) . The cysteine-active site and peptide sequence of CAST provides specificity for many inhibitors over other families of proteases (e.g., serine and aspartic proteases), but selectivity between cysteine proteases remains a challenge. Most calpain inhibitors are not specific and inhibit other cysteine proteases (Ono et al., 2016) . Thus, most calpain inhibitors, to date, are too broad for clinical use. Here, we present a highresolution structure of human CAPN5-PC along with detailed functional and biophysical analysis.
RESULTS

Broad Phylogenetic Analysis Reveals Conserved
Residues that Are Unique to CAPN5 Calpains exhibit broad structural conservation of their protease core domains despite being highly divergent in their respective domain topologies. Nevertheless, broad sequence-based phylogenetic analysis could reveal unique features among calpain protease cores that have co-evolved to accommodate their respective non-catalytic domains (Masrati et al., 2018) . We aligned a seed group of manually curated calpain sequences that share the protease core fold and produced a profile hidden Markov model (HMM) ( Figure 1C ) (Finn et al., 2011) . The profile HMM was then used in a HMMER search to broaden the pool of calpain sequences. A fast approximation of the unrooted calpain superfamily tree (5,284 taxa) was constructed ( Figure 1D ) (Price et al., 2010) . The resulting phylogenetic tree divided the calpain superfamily into clades based on their domain architecture ( Figure S1 ). The CAPN5-like sequences were extracted from the approximated tree and aligned to construct a neighbor-joining maximum-likelihood tree (454 taxa) ( Figure 1E ). The CAPN5 sub-tree was divided into clades representing groups of related organisms. Despite the high diversity among the CAPN5 sequences, we identified 68 residues that were 100% conserved in chordates across evolution (Table S1 ). Of these 68 residues, 47 (69%) were localized to the PC domain, highlighting their functional importance in maintaining CAPN5 activity.
The Crystal Structure of CAPN5-PC Reveals an Inactive Conformation
We solved the crystal structure of the wild-type (WT) human CAPN5-PC in an inactive conformation. The crystals diffracted to 2.8 Å resolution and contained two molecules in the asymmetric unit (Table 1) . No electron density was seen for the C-terminal 6x His tag of the construct, Ca 2+ ions, or a peptide present in the crystallization solution (see STAR Methods). Alignment of the two molecules in the asymmetric unit yielded a rootmean-square deviation (RMSD) of 0.13 Å across 315 Ca atoms. The overall architecture (residues 4-349 in the construct) retained the conventional mixed a/b structure seen in other calpain protease cores: the catalytic subdomains (PC1 and PC2) were connected by a flexible linker (Figure 2A ). There was one Ramachandran outlier present in the structure (Asp201 in chain B) ( Table 1) . This residue was located at the a8 helix, where the density map was slightly ambiguous. Nevertheless, the backbone continuity was sound near this residue. We anticipate that higher-resolution structures will resolve this outlier. ConSurf analysis was performed using the CAPN5-PC structure and the 454 CAPN5 sequences as input (Armon et al., 2001; Ashkenazy et al., 2016; Glaser et al., 2003) . As expected, residues comprising CAPN5-PC's hydrophobic core and active site groove displayed high evolutionary conservation scores and were among the 68 residues that were 100% conserved (Figure 2B ; Table S1 ). The imidazole nitrogen (NE2) of His252 was located 3.7 Å away from the thiol sulfur (SG) of Cys81 (Figures 2C and S2) . The orientation of the conserved tryptophan ''wedge '' residue (Trp286) in the active site groove precludes formation of the catalytic triad and forms p-p stacking interactions with His252 ( Figure 2C ). In active Ca 2+ -bound calpain protease core structures, the tryptophan wedge residue is displaced from its position between PC1 and PC2, allowing for formation of the fully competent catalytic triad (Moldoveanu et al., 2004b) . Therefore, the unformed nature of the catalytic triad in our CAPN5-PC structure indicates it was in an inactive conformation (Otto and Schirmeister, 1997; Storer and Mé nard, 1994) .
To date, calpain inhibitor design has utilized the G1 gating loop as a conformational and sequential specificity determinant (Cuerrier et al., 2006; Moldoveanu et al., 2004a; Qian et al., 2008) . We compared G1 loop conformations across known calpain structures ( Figure S3A ). Interestingly, the CAPN5-PC G1 loop adopted a conformation similar to that of certain active (Ca 2+ -and inhibitor-bound) calpain structures (e.g., leupeptin-, E-64-, and SNJ-1715-bound CAPN1) despite being in an inactive Ca 2+ -free state ( Figure S3A ). Because calpain activation requires a connection between the protease core subdomains, inhibition of this interaction through intercalation between PC1 and PC2 may be a viable strategy for designing CAPN5-specific inhibitors (Ono et al., 2016) . These observations suggest that the inactive CAPN5-PC structure may serve as a usable template for rational inhibitor design. The CAPN5-PC structure had an inter-domain rotation angle of 19 with respect to its flexible linker when compared to the Ca 2+ -bound (active) human CAPN1-PC (PDB: 2ARY) ( Figure S3B ). This observed rotation angle corresponds to a more ''open'' conformation with respect to PC1 and PC2 compared to the ''closed'' conformations observed for active calpains. The relative domain rotation observed for CAPN5-PC was closed compared to conformations observed for inactive classical calpains (e.g., rat CAPN1-like, PDB: 1QXP) ( Figure S3B ), which contain rotation angles ranging from 23 C to 26 C. Previous small-angle X-ray scattering-guided (SAXS) modeling of CAPN5-PC in the absence of added Ca 2+ by our group revealed a highly open conformation (Gakhar et al., 2016) . It is unclear whether crystal packing influenced the conformation observed in our CAPN5-PC structure. We anticipate that Ca 2+bound or inhibitor-bound structures of CAPN5-PC will address this question. Calpains contain an intrinsic reversible mechanism to inhibit the autolysis-generated protease core (Davis et al., 2007; Moldoveanu et al., 2003) . This mechanism is mediated through instability of the a7 helix on PC1 in the absence of their non-catalytic domains (Moldoveanu et al., 2003) . In classical calpains, instability of this a-helix in the vicinity of the active site is thought to cause a rearrangement of a nearby tryptophan side chain (Trp82) into the active site cleft, preventing formation of the catalytic triad. Calpain paralogs, containing a destabilizing glycine residue in the a7 helix, are predicted to be susceptible to this intrinsic silencing mechanism (e.g., human CAPN1, CAPN2, CAPN8, and CAPN11) (Moldoveanu et al., 2003) . Conversely, alanine-containing protease cores, such as human CAPN5-PC and the highly catalytic rat CAPN1-PC, are expected to generate stable a7 helices, allowing them to be active in the absence of their respective non-catalytic domains (Moldoveanu et al., 2003) . Indeed, we found that CAPN5-PC contained a well-formed a7 helix ( Figure 2D ) compared to the weakly catalytic human CAPN1-PC (PDB: 2ARY) ( Figure 2E ). This observation suggested that human CAPN5-PC could also be active in the absence of its CBSW and C2 domains.
The Calpain-5 Protease Core Undergoes Ca 2+ -Induced Conformational Changes Thermostability was analyzed by recording differential scanning fluorimetry (DSF) data at different Ca 2+ concentrations as CAPN5-PC was heated from 4 C to 95 C. With increasing amounts of Ca 2+ , the half-maximal change in melting temperature, T melt (DSF K d ), was observed at 2.5 ± 0.3 mM ( Figure S4A ), suggesting that CAPN5-PC displays Ca 2+ -stabilization in the millimolar range. Conformational changes of PC1-PC2 were measured in a standard calpain assay (Moldoveanu et al., 2002 (Moldoveanu et al., , 2003 (Moldoveanu et al., , 2004b . A sigmoidal increase in intrinsic tryptophan fluorescence (IWF) was observed in response to increasing Ca 2+ concentrations. Half-maximal change in fluorescence occurred at 6.3 ± 1.0 mM Ca 2+ ( Figure 3A) . The observed Ca 2+ requirement for thermostability and increase in IWF signal indicated CAPN5-PC requires millimolar Ca 2+ concentrations to achieve a conformational change. We performed SAXS analysis to gain better insight into CAPN5-PC's behavior in solution. CAPN5-PC samples were thoroughly dialyzed against the SAXS buffer with either 5 mM EDTA (Ca 2+ -free) or 10 mM CaCl 2 (Ca 2+ -bound). Our DSF and IWF data suggested that 10 mM CaCl 2 would be sufficient to induce a conformational change that could be observed with SAXS. The merged scattering profiles for both samples displayed no signs of aggregation or radiation damage based on the Guinier plot at low q values ( Figure 3B ). Kratky plots adopted a bell-shaped curve for both samples, indicating that they were globular and well-folded ( Figure S4B ). The pairwise distance distribution P(r) function for both samples revealed distinct distribution profiles despite the subtle change in D max between Ca 2+free (D max = 69 Å ) and Ca 2+ -bound CAPN5-PC (D max = 64 Å ) (Figure 3C ; Table S2 ). The Ca 2+ -free CAPN5-PC displayed a more extended shape in solution (R g = 23.7 ± 0.3 Å ) than the Ca 2+bound form (R g = 21.9 ± 0.3 Å ). Theoretical scattering patterns calculated from our crystal structure were in agreement with the experimental scattering data for Ca 2+ -free CAPN5-PC (c 2 = 1.55). The theoretical scattering pattern of our CAPN5-PC structure was a relatively poor fit to the experimental scattering profile for Ca 2+ -bound CAPN5-PC (c 2 = 8.58) ( Figure 3D ), further supporting that the crystal structure conformation was more consistent with an inactive state.
The Calpain-5 Protease Core Requires High Calcium Concentrations for Maximal Enzymatic Activity We probed CAPN5-PC activity using in vitro fluorescence resonance energy transfer (FRET) assays measuring hydrolysis of synthetic oligopeptides. When assayed with N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin (sLY-AMC), CAPN5-PC was catalytically active in the presence of 10 mM Ca 2+ and inactive in the presence of 5 mM EDTA (data not shown) (Sasaki et al., 1984) . A catalytically inactive version of this enzyme, carrying a p.C81S mutation, displayed no observable activity ( Figure 3E ). The steady-state kinetic parameters of sLY-AMC hydrolysis by CAPN5-PC in the presence of 10 mM Ca 2+ (k cat = 7.4 3 10 À5 ± 3 3 10 À6 s À1 , K m = 131 ± 18 mM) fell in the range of values reported previously for classical calpain cores ( Figure 3F ; Table  S3 ) (Davis et al., 2007; Moldoveanu et al., 2002 Moldoveanu et al., , 2003 Moldoveanu et al., , 2004b . We also assayed CAPN5-PC with another synthetic calpain substrate, Ac-Leu-Leu-Tyr-7-amino-4-trifluoromethylcoumarin (Ac-LLY-AFC), which displayed higher catalytic efficiency over sLY-AMC in the presence of 10 mM Ca 2+ (k cat = 1.2 3 10 À2 ± 8 3 10 À4 s À1 , K m = 153 3 10 2 ± 38 mM).
A Ca 2+ titration in the presence of 0.1 mM Ac-LLY-AFC revealed that the half-maximal activity of CAPN5-PC occurred at (I 340 ) was monitored at 340 nm by exciting at 280 nm at varying Ca 2+ concentrations. Data are fit to the Hill equation (R 2 = 0.75) and are displayed as mean ± SEM (n = 3). (B) Scaled buffer-subtracted scattering curves for CAPN5-PC in the presence of 5 mM EDTA or 10 mM Ca 2+ . The linear portion of the Guinier region is displayed in the inset (R 2 = 0.95 and 0.93 for Ca 2+ -free and Ca 2+ -bound CAPN5-PC, respectively). (C) Pairwise distance distribution function P(r) of the averaged data. (D) Theoretical scattering patterns calculated from the CAPN5-PC structure showing agreement with the experimental data (c 2 = 1.55 and 8.58 for Ca 2+free and Ca 2+ -bound, respectively). (E) Fluorescence tracing of sLY-AMC (0.4 mM) hydrolysis by 10 mM CAPN5-PC (WT or p.C81S) in the presence of 10 mM Ca 2+ . (F) Michaelis-Menten analysis of sLY-AMC hydrolysis by 10 mM CAPN5-PC in the presence of 10 mM Ca 2+ (R 2 = 0.96). Data is displayed as mean ± SEM (n = 3). (G) Effect of increasing concentrations of Ca 2+ on Ac-LLY-AFC hydrolysis (0.1 mM) by 0.5 mM CAPN5-PC. Data are fit to the Substrate-Inhibition equation (R 2 = 0.96). CAPN5-PC activity at mM Ca 2+ levels (inset). Data are fit to the Hill equation (R 2 = 0.97) and displayed as mean ± SEM (n = 3). (H) Inhibition of Ac-LLY-AFC hydrolysis (0.2 mM) by 0.5 mM CAPN5-PC in the presence of 10 mM Ca 2+ by E-64 or hCAST-B27. Data were fit to the Hill equation (R 2 = 0.98 and 0.94 for E-64 and hCAST-B27, respectively) and displayed as mean ± SEM (n = 3). 12 ± 4 mM Ca 2+ ( Figure 3G ). This Ca 2+ requirement is orders of magnitude higher than the reported [Ca 2+ ] for half-maximal activity of the classical calpains CAPN1 and CAPN2 (3-50 mM and 200-1,000 mM, respectively) (Goll et al., 1992) . CAPN5-PC displayed modest activity in the micromolar range ( Figure 3G , inset). This high Ca 2+ requirement could be an evolutionary adaptation for CAPN5's expression in tissues with high basal Ca 2+ levels. Interestingly, we observed a reduction in CAPN5-PC activity at Ca 2+ concentrations >50 mM, suggesting that high Ca 2+ levels may serve as an additional layer of regulation for CAPN5 activity. The Ca 2+ -requirement for CAPN5-PC activity in vitro is orders of magnitude higher than the nanomolar [Ca 2+ ] observed in cells (Campbell and Davies, 2012) , although the physiological relevance of the protease core alone is not known. It is hypothesized that localized increases in [Ca 2+ ] result in transient calpain activation (i.e., influx at the site of a Ca 2+ -channel). Indeed, total intracellular [Ca 2+ ] can increase up to three times the resting level during neuroinflammation (Hoffmann et al., 2003) . CAPN5-PC activity was inhibited by E-64 (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)-butane; IC 50 = 1.2 ± 0.3 mM), a broad irreversible cysteine protease inhibitor, and the human CAST B27 peptide (residues 184-210; IC 50 = 1.0 ± 0.2 mM) ( Figure 3H ) (Betts et al., 2003) . Taken together, these results confirm that CAPN5-PC displays Ca 2+ -sensitive enzymatic activity characteristic of calpains but has varied proteolytic activity for different synthetic calpain substrates. Although CAPN5-PC activity can be inhibited by the B27 peptide in vitro, the full-length CAPN5 protein lacks the PEF-hand domains required to bind the full-length CAST (Hanna et al., 2008) . Therefore, it is unlikely that CAST significantly inhibits CAPN5 activity in vivo, and other forms of regulation are important for this non-classical calpain.
Structure-Based Phylogenetic Analysis Reveals Unique Features in CAPN5-PC Are Absent in Classical Calpains
Although very divergent in their sequences and functions, calpains display remarkable similarity in the 3D structure of their protease cores (Campbell and Davies, 2012; Matena et al., 1998; Ono and Sorimachi, 2012) . This structural similarity has presented challenges in the design of specific therapeutic inhibitors, because most calpain inhibitors are active-site directed (Ono et al., 2016) . Thus, determining subtle structural similarities and differences between calpain protease cores would aid in the design of calpain-specific inhibitors. Earlier sequence-based phylogenetic studies of calpain paralogs highlighted that they have a long evolutionary history and are highly conserved across multiple species (Matena et al., 1998) . However, the structural basis of their functional diversity is not completely understood, especially with regards to non-classical calpains. Primary sequence alignments and secondary structure predictions often miss key differences between structures due to the complexity of modeling non-local interactions between residues that are far away in their relative sequence position but are close in 3D space (Dill and MacCallum, 2012; Dill et al., 2008; Yang et al., 2018) . Diversity in the length and composition of flexible loop regions can also produce large variations in sequence-based alignments (Carpentier and Chomilier, 2019) . We therefore utilized a structure-based phylogenetic approach to examine the functional diversity among calpain protease cores (Balaji and Sri nivasan, 2007) . Twenty-six calpain protease core structures have been solved in the presence or absence of bound Ca 2+ or an inhibitor (CAPN1, CAPN2, CAPN3, CAPN8, and CAPN9) (Davis et al., 2007; Moldoveanu et al., 2002; Ye et al., 2018) . These structures were evaluated by their reported global validation metrics in PDB-REDO, including R free , Clashscore, Ramachandran outliers, side chain outliers, and normalized real-space R value outliers (Gore et al., 2017; Joosten et al., 2009 ). Structures meeting at least 3 out of the 5 metrics (20 structures total) were used in the analysis. Structures not meeting these criteria were excluded. Pairwise structural comparisons of PC1 and PC2 domains were used to calculate structural dissimilarity matrices (SDM) based on the RMSD between protein alpha carbon (Ca) atoms (Zhu et al., 2010) . Structure-based phylogenetic trees were then generated from these SDM matrices using the unweighted pair group method with arithmetic mean (UPGMA) (Sneath and Sokal, 1973) .
The structural phylogenetic tree for PC1 showed separation of calpain structures in two distinct clusters with a majority of structures grouped in the first cluster ( Figure 4A ). Interestingly, CAPN5 clustered separately from the other calpain PC1 structures. Superimposition of PC1 structures from this analysis revealed conformational differences with respect to their flexible loop regions ( Figure 4B ). Notably, CAPN5 PC1 contained a flexible, surface-exposed loop that was longer than corresponding loops on classical calpain structures. We termed this loop PC1L1, denoting its position on the PC1 domain and proximity to the N terminus ( Figure 4B ). Repeated analysis excluding the flexible loop regions showed similar separation of CAPN5 from classical calpain structures based on secondary structure elements alone ( Figure S5 ). The structural phylogenetic tree for the PC2 domain similarly showed separation of calpain structures in two distinct clusters (Figures 4C and 4D) . Interestingly, CAPN5's PC2 domain contained two additional, elongated surface-exposed loops, which we termed PC2L1 and PC2L2 (denoting their proximity to the C terminus) ( Figure 4D ). Multiple sequence alignment of calpain isoforms revealed that these flexible loops correspond to ''gaps'' within the target-template alignment (Figures S6 and S7) . Although the presence of these loops could be predicted from the primary sequence alignment, a detailed structure-based comparison provided more precise information on the secondary structure elements on these loops and their surrounding regions ( Figure 4D ). Additionally, CAPN5-PC contained an elongated a8 helix and several elongated b strands compared to classical PC2 domains ( Figure 4D ). Thus, without a crystal structure or accurate template, one could not reliably infer the presence of these motifs from the primary sequence alone. Interestingly, we observed variable evolutionary conservation scores among residues in the three elongated flexible loops on ConSurf analysis. Residues in the PC1L1 loop were highly conserved, while the PC2L1 loop displayed considerable variability ( Figure 4E ). The N-terminal region of the PC2L2 loop was highly conserved, while its a-helical residues were variable ( Figure 4E ). Taken together, these data reveal the presence of three elongated flexible loops on CAPN5-PC of unknown function that are sequentially conserved and structurally unique to CAPN5 compared to classical calpains.
Disease-Causing Mutation in the Unique CAPN5 PC2L2 Loop Reveals a Regulation Mechanism for Calpain Activity
We next mapped known NIV mutations to the CAPN5-PC structure: p.R243L, p.L244P, p.K250N, p.G267S, and p.R289W (Figures 5A and 5B) . Interrogation of our sequence-based phylogenetic data revealed the percent conservation (among chordates) of residues at NIV mutation sites: Arg243 (68.3%), Leu244 (73.3%), Lys250 (81.3%), Gly267 (81.3%), and Arg289 (53.1%). Interestingly, a previously identified patient mutation (CAPN5 c.799G>A, p.Gly267Ser) mapped to the PC2L2 loop on CAPN5-PC (Randazzo et al., 2019) . This de novo heterozygous missense mutation was different than previously identified NIV mutations; it was not located on a gating loop near the active site ( Figure 5B ). The PC2L2 loop connects two b strands that contain the catalytic His252 and Asn284, suggesting that it may regulate CAPN5 activ- ity through remote mechanisms( Figure S2 ). The patient harboring this mutation was a 44-year-old Caucasian male with a severe NIV phenotype and advanced disease ( Figures 6A-6H ). The patient displayed progressive visual problems from infancy with myopia, congenital nystagmus, and optic nerve myelination. By 19 years, the patient developed progressive, severe vitreoretinopathy, which resulted in subretinal exudative fluid and fibrosis leading to bilateral tractional retinal detachments. He later developed neovascular glaucoma in his fourth decade of life. The presence of this mutation on the PC2L2 loop suggested a functional role for this flexible region in regulating CAPN5 activity. We purified CAPN5-PC p.G267S and validated its correct folding by circular dichroism (CD) spectroscopy ( Figure S8 ). The kinetic parameters for sLY-AMC hydrolysis by CAPN5-PC p.G267S (k cat = 1 3 10 À4 ± 5 3 10 À6 s À1 , K m = 153 ± 18 mM) indicated it was hyperactive ( Figure 6I ; Table S3 ). Introduction of p.G267S mutation led to an increase in substrate turnover and catalytic efficiency, confirming that this PC2L2 loop mutation results in a hyperactivity. This subtle change in k cat is biologically meaningful due to the slow timescale of NIV disease progression. Patients are not born with the disease, and NIV often takes 20 or more years to develop (Bassuk et al., 2015; Mahajan et al., 2012; Velez et al., 2017 Velez et al., , 2018 Wert et al., 2015) . DSF and IWF results for CAPN5 p.G267S were indistinguishable from WT (data not shown) suggesting its hyperactivity was independent of Ca 2+ -induced conformational changes or stabilization. We therefore hypothesized that this loop's length and dynamics Cell Reports 30, 881-892, January 21, 2020 887 may be evolutionarily designed to remotely regulate calpain activity. Using a synthetic biology approach, we introduced the CAPN5 PC2L2 loop (residues 260-275) into rat CAPN1-PC, a Figure 5 . Disease-Associated Mutations in CAPN5-PC (A) Multiple sequence alignment of PC2 from human calpain paralogs showing the location of NIV-causing mutations and functional residues on the primary structure. The p.G267S mutation is located on the PC2L2 loop shared between CAPN5 and CAPN6. (B) Ribbon tracing representation of CAPN5-PC (light gray) highlighting location of mutations implicated in NIV. Green ribbon, G1 gating loop; pink ribbon, G2 gating loop; orange ribbons, PC1L1, PC2L1, and PC2L2 loops. very distant calpain in terms of sequence and structural phylogeny (Figures 1D and 4) . A recombinant CAPN1/5 hybrid molecule was created ( Figure 6J ) and purified with an N-terminal maltose binding protein (MBP) tag, which was more stable than the untagged enzyme (data not shown). The WT MBP-rCAPN1/5-PC hybrid molecule was catalytically active and hydrolyzed sLY-AMC. Introduction of the p.G267S mutation into the CAPN1/5 hybrid similarly led to an increase in activity, confirming that the PC2L2 loop can remotely regulate catalytic activity across $43 Å ( Figure 6K ). (I) Michaelis-Menten analysis of sLY-AMC hydrolysis by 10 mM WT and p.G267S CAPN5-PC in the presence of 10 mM Ca 2+ (R 2 = 0.96 and 0.96 for WT and p.G267S, respectively). Data are displayed as mean ± SEM (n = 3). (J) Schematic representation of hybrid calpain constructs. Alignment of the PC2L2 loop region between human CAPN5, rat CAPN1, and the rat CAPN1/5 hybrid is represented below. SS denotes secondary structure annotations corresponding to CAPN5-PC. (K) Hydrolysis of 0.2 mM sLY-AMC by 10 mM MBP-rCAPN1/5 (WT and p.G267S) in the presence of 10 mM Ca 2+ .
DISCUSSION
Calpain hyperactivity is implicated in a number of neurodegenerative diseases, and gain-of-activity mutations in CAPN5 cause NIV. However, the mechanisms underlying CAPN5's role in the pathogenesis of NIV are poorly understood. The regulatory roles of classical calpains in mediating neuronal cell death and necrosis have been extensively studied, including the cleavage of JNKinteracting protein-1 and Bax, which trigger activation of cell death signaling pathways (Cheng et al., 2018; Wert and Mahajan, 2019) . Aberrantly activated calpains (e.g., CAPN1 and CAPN2) also process a number of substrates in the CNS that promote cell necrosis, including vimentin, tubulins, and integrins (Azuma and Shearer, 2008; Cheng et al., 2018) . These calpain-mediated events are thought to contribute to the pathogenesis of several neurodegenerative diseases, including retinal degeneration and hypoxia-induced glaucoma (Azuma and Shearer, 2008; Cheng et al., 2018; Huang et al., 2010) . Detailed structural studies of classical calpains have revealed mechanistic insights into the substrate specificity between calpain isoforms (Moldoveanu et al., 2004a) . The calpain active site is gated by two flexible loops on each side of the active site cleft. It is hypothesized that these loops mold around substrates and that the sequence variations in these loops confer specificity to calpain substrates and inhibitors (Moldoveanu et al., 2004a) . We have previously demonstrated that activity of CAPN1 can be altered by the substitution of CAPN5 gating loops, with and without NIV disease mutations (Wert et al., 2015) . It is unclear, however, if CAPN5 contributes to NIV pathogenesis through distinct or overlapping mechanisms and if it processes the same protein targets as CAPN1 and CAPN2 in the retina. Furthermore, the structural basis by which NIV mutations cause CAPN5 hyperactivity is poorly understood. These knowledge gaps highlight the need for detailed structural and functional studies of non-classical calpains, like CAPN5.
Here, we present the high-resolution structure of a non-classical calpain protease core. Most crystal structures of calpains that have been determined are activated forms (with bound Ca 2+ ions and the catalytic triad in formation). It has been difficult to crystallize calpains without the active site cysteine-to-serine/ alanine mutation (e.g., p.C81S). Here, we report the structure of the WT (no inactivating mutation) Ca 2+ -free CAPN5 protease core. We identified several unique features of CAPN5-PC: it contains elongated flexible loops (PC1L1, PC2L1, and PC2L2) and an elongated a8 helix compared to its classical counterparts ( Figure 4 ). Although the functional significance of most of these regions remains unknown, the presence of the p.G267S mutation on the PC2L2 loop indicates a role for this region in regulating enzyme activity. This suggests that these features have co-evolved with CAPN5's unique domain topology. Our ability to transfer this regulatory mechanism into rat CAPN1 by swapping in the CAPN5 PC2L2 loop supports the concept of an evolutionary mechanism for fine-tuning calpain function and activity by modifying the flexible loops. Furthermore, the identification of this unique structural motif on CAPN5-PC suggests that this region may be an attractive target for the design of specific allosteric inhibitors for CAPN5.
Previously identified NIV mutations in the PC2 domain are in close proximity to the active site groove and are predicted to disrupt regulatory motifs that would otherwise prevent aberrant CAPN5 activity. For example, the p.R243L, p.L244P, and p.K250N mutations are predicted to disrupt the gating function of the G1 loop, which may leave the active site groove accessible to substrates, even in the absence of Ca 2+ ( Figure 5B ) (Bassuk et al., 2015; Mahajan et al., 2012; Velez et al., 2018) . The p.G267S mutation, however, is located far from the active site in a solvent-exposed region of the structure. The PC2L2 loop did not appear to make significant interactions with the rest of the PC2 domain nor the neighboring molecules. However, substitution from a glycine to a serine in this region may affect the dynamics or hydrogen-bonding network of this loop and could confer hyperactivity through remote effects. Interestingly, the phenotype of the p.G267S patient is distinct from originally identified NIV kindreds. In these original pedigrees, disease onset did not begin until the second decade of life. However, the p.G267S patient displayed pediatric retinal disease, suggesting a genotype-phenotype correlation that may link enzymatic activity to disease severity. This correlation is supported by our previously published studies on the G1 loop mutations (e.g., p.R243L) (Wert et al., 2015) and the syndromic, pediatric NIV variant (p.R289W) (O'Keefe et al., 2019; Velez et al., 2018; Wang et al., 2018) . More detailed kinetic studies of additional CAPN5 NIV mutants are required to determine if the level of hyperactivity correlates to disease onset and/or severity. Due to the location of the p.G267S mutation on a surface-exposed loop, it is possible that alterations in this region may affect protein-protein interactions. However, we observed a similar relative hyperactivity in the CAPN1/5 chimera in the absence of non-catalytic domains and binding partners. At this stage, we cannot formally exclude the possibility of the mutation affecting interactions with noncatalytic domains and/or other proteins, which would require future research on the full-length CAPN5 and identification of cognate interaction partners in the retina.
Our functional analyses addressed the activity and Ca 2+ dependence of CAPN5-PC in vitro. IWF and SAXS revealed that CAPN5-PC undergoes a conformational change in the presence of Ca 2+ . A high-resolution structure of the Ca 2+ -bound CAPN5-PC would also reveal more detailed structural rearrangements that occur during this transition as well as elucidate the locations of its Ca 2+ -binding sites. We established that CAPN5-PC is active even in the absence of its CBSW and C2 domains and that it displays characteristic calpain activity when assayed with common calpain substrates. The observation that CAPN5-PC hydrolyzes similar peptide substrates suggests that there is some overlap in the protein targets of classical and non-classical calpains (Figure 3 ). Although we observe hyperactivity of CAPN5-PC p.G267S toward sLY-AMC, it is unclear if this would translate to hyperactivity toward the endogenous retinal substrates responsible for NIV development. Identification of the natural retinal substrates of CAPN5 will determine which signaling pathways are affected by hyperactivity. Our enzymatic studies also revealed the high Ca 2+ requirements of CAPN5-PC activation in vitro. Interestingly, studies with CAPN2 showed that phosphorylation at Ser50 by extracellular signal related kinase (ERK) reduced the enzyme's Ca 2+ requirement for activation (Glading et al., 2004) . It is possible that post-translational modifications of CAPN5 may reduce its high Ca 2+ requirement in vivo. The relatively low catalytic efficiency of CAPN5-PC in vitro may be attributed to the lack of structural support from its non-catalytic domains. This phenomenon has been observed for classical calpain cores (e.g., CAPN1), which display only 5%-10% of the activity of the whole enzyme (Campbell and Davies, 2012) . Another possible explanation for the observed low k cat is that sLY-AMC and Ac-LLY-AFC are not natural or preferred substrates for CAPN5. These findings highlight the need to study enzymatic activity, Ca 2+ dependence, and effects of disease-causing variants using the full-length CAPN5 protein and validated natural substrates.
While classical calpain regulation has been extensively studied, the mechanisms underlying CAPN5 regulation remain poorly understood (Campbell and Davies, 2012; Goll et al., 1992) . CAST inhibits classical calpain activity by forming interactions with all five domains (Campbell and Davies, 2012; Hanna et al., 2008) .
Although our experiments show that CAPN5-PC activity can be inhibited by the CAST inhibitory region (B27 peptide) in vitro, the full-length CAPN5 protein does not contain the classical calpain domains required to bind full-length CAST. Therefore, it is likely that other forms of regulation are important. We anticipate that isolation of CAPN5-binding partners will further our understanding of its regulation at the cellular level. Our enzymatic studies revealed that CAPN5-PC requires millimolar concentrations of Ca 2+ for maximal activity in vitro, similar to CAPN2. Because CAPN5 is highly expressed in cells with high resting concentrations of Ca 2+ , such as retinal photoreceptors ($300-700 nM) and intestinal epithelial cells ($140 nM), this high Ca 2+ requirement may provide an additional safeguard to prevent aberrant CAPN5 activity in these cells (Brunet et al., 2000; Krizaj and Copenhagen, 2002; Schaefer et al., 2016 Schaefer et al., , 2017 . Our data provide important insight into the structural and functional mechanisms of CAPN5 activation and highlight unique characteristics of this disease-associated protein.
Further structural and functional studies of CAPN5 will elucidate the mechanisms underlying NIV pathogenesis and guide the design of specific inhibitors to treat this blinding eye disease.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell lines
Escherichia coli BL21 (DE3) cells were used for calpain expression and crystallization.
Patients
The patient described in the study was a 44-year-old Caucasian male with end-stage NIV disease harboring a CAPN5 c.799G > A, p.Gly267Ser mutation. The study adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients for study participation as per standard NHS Trust policy.
METHOD DETAILS
Clinical testing
Peripheral blood samples were taken for next generation DNA sequencing as previously described (Randazzo et al., 2019) . Clinical ophthalmic imaging (fundus photography, infrared imaging, fluorescein angiography, and spectral domain optical coherence tomography) was obtained with the Optos ultra-widefield camera and Heidelberg Spectralis Tracking Laser Tomography (v 6.6.2). 
Sequence-based phylogenetic analysis
We first searched the UniProt database for reviewed entries denoted as calpains (containing a calpain protease core domain). This initial search yielded a total of 57 manually curated sequences. A seed multiple sequence alignment (MSA) was then constructed by using MAFFT v7 with default parameters (alignment strategy: FFT-NS-1) (Katoh and Standley, 2013) . Using HMMER-3.1 and the seed alignment we produced an HMM profile and used it to broaden the search against the UniProt database (which was restricted to the phylum Chordata) (Finn et al., 2011) . This search yielded a total of 8,113 proteins. We discarded fragmented sequences (< 300 amino acids) that appeared too short to truly represent the full protease core domain fold and redundant proteins were further filtered using CD-HIT v4 with a threshold of 100% sequence identity (Li and Godzik, 2006) . This resulted in a pool of 5,284 proteins that were aligned using MAFFT v7 (alignment strategy FFT-NS-2) (Katoh and Standley, 2013) . We used FastTree v2 to generate a fast approximation of the unrooted phylogenetic tree for the large pool of calpain sequences. Sequences representing the CAPN5 sub-tree (522 sequences) were extracted and realigned using MAFFT v7 (alignment strategy: FFT-NS-1) (Price et al., 2010) . Taxa (sequences) producing many gaps in the alignment were removed using MaxAlign (Gouveia-Oliveira et al., 2007) . Phylogenetic tree reconstruction of the CAPN5 family sub-tree (454 sequences) was performed using Geneious Tree Builder, Jukes-Cantor distance model, and Neighbor-Joining tree build method with 100 bootstrap replicas. Sequence logos were generated using Skylign (http://www. skylign.org).
Cloning and protein expression
Calpain protease core domain (PC1-PC2) sequences (residues 1-343) were cloned into a pUC57 vector with an Xho I restriction site, with an N-terminal thrombin cleavage site, and a C-terminal TEV protease cleavage site followed by a 6xHis tag, as previously described (Gakhar et al., 2016; Velez et al., 2018) . Calpain constructs were transferred into the pMAL-C5X vector to obtain an N-terminal maltose binding protein (MBP) as a fusion partner that could be cleaved off with thrombin. Sequence of the calpain flanking regions was confirmed by sequencing of constructs. Plasmids were amplified and isolated from DH5a cells and then transformed into E. coli BL21 (DE3).
Protein expression and purification
For structural studies, samples of CAPN5-PC were prepared to a purity greater than 95%, as described below. E. coli BL21 (DE3) cells expressing CAPN5-PC were grown in 1 L shake-flask cultures, at 250 rpm in Terrific Broth (Invitrogen), at 37 C until an OD 600 of 1.0 and then induced with 0.2 mM IPTG. Cells were grown at 16 C for 19 hours, harvested, and centrifuged at 4,000 x g for 20 minutes and pellets (40 mL per Liter of cell culture) were re-suspended immediately or frozen at À20 C for later use. Cell pellets were re-suspended in 35 mL of lysis buffer (20 mM HEPES, 300 mM NaCl, 2 mM DTT, pH 7.5, one tablet of EDTA-free protease inhibitor (Roche), DNase (Roche)) and lysed using a sonic dismembrator (Fisher Model 705) and centrifuged for 1 hour at 18,000 x g at 4 C. Cell debris was discarded and the supernatant (30 mL) loaded onto a gravity-flow column packed with 15 mL (1CV) amylose resin (New England Biolabs). The column was washed with 5 to 10 CV of wash buffer (20 mM HEPES, 300 mM NaCl, pH 7.5) and eluted with 6 to 8 CV of elution buffer (20 mM HEPES, 300 mM NaCl, 10 mM maltose, pH 7.5). Eluted fractions were pooled and concentrated to 2 mL at 12 mg/mL (30 kDa NMWL spin concentrator; Millipore). MBP was removed with thrombin (1 units/mg of protein; thrombin from bovine plasma, T7201, Sigma-Aldrich) at 4 C for 16 hours and the reaction mix passed over Ni-NTA (QIAGEN) resin to remove cleaved-off MBP using 6 CV wash buffer (20 mM HEPES, 500 mM NaCl, 10 mM Imidazole, glycerol, pH 7.5). Cleaved and remaining un-cleaved CAPN5-PC was eluted with 5 CV of elution buffer (20 mM HEPES, 500 mM NaCl, 200 mM Imidazole, 5% glycerol, pH 7.5). The eluted protein was concentrated with a 10 kDa NMWL spin concentrator and passed over a Superdex 75 (GE) size-exclusion (SEC) column connected to an Ä TKA TM pure fast protein liquid chromatography (FPLC) system (GE Healthcare Inc.) to remove residual, un-cleaved fusion protein. The column was equilibrated with elution buffer (20 mM HEPES, 150 mM NaCl, 2 mM DTT, 5% glycerol, pH 7.5). For kinetic studies, samples of CAPN5-PC were prepared as described above, but with Tris-HCl instead of HEPES (Gakhar et al., 2016; Velez et al., 2018; Wert et al., 2015) . Purity was assessed at each step on Coomassie-stained SDS-PAGE gels.
Crystallization and structure determination Crystallization of the wild-type human CAPN5-PC was performed by the hanging drop vapor diffusion method at 18 C. Prior to addition to the drop, the final protein concentration was 10 mg/mL in 20 mM HEPES (pH 7.5), 150 mM NaCl, 2 mM DTT, and 5% glycerol. Crystals (soft, thin plates) initially grew overnight in 100 mM NaH 2 PO 4 (pH 6.5) and 12% PEG 8000 (ProPlex HT-96 Screen, Molecular Dimensions). Optimization was carried out by screening around the initial hit condition with the addition of EDTA (from 0 to 75 mM) and/or CaCl 2 (10 mM). Diffraction-quality crystals (large plates) were grown by mixing protein 1:1 with a reservoir solution containing 250 mM NaH 2 PO 4 (pH 6.0), 12% PEG 8000, 36 mM EDTA, 10 mM CaCl 2 . Crystals grew thicker with the addition of 0.4 mM H-E(EDANS)-KIEIVRKKPIFKKATV-K(DABCYL)-OH peptide (Biopeptek) to the protein solution prior to mixing reservoir solution. Diffraction data were collected on flash-cooled crystals at the 4.2.2 beamline (Advanced Light Source, Lawrence Berkeley National Laboratory). Crystals belonged to the P 1 2 1 1 space group with two molecules per asymmetric unit. The datasets were indexed, integrated, and scaled using XDS (Kabsch, 2010 
ConSurf analysis
The CAPN5-PC crystal structure was used as input for analysis in the ConSurf server (Armon et al., 2001; Ashkenazy et al., 2016; Glaser et al., 2003) . The 454 CAPN5 sequences from our sequence-based phylogenetic analysis underwent multiple sequence alignment using MAFFT and conservation scores were calculated using the Bayesian method option in ConSurf as previously described (Katoh and Standley, 2013; Wert et al., 2019) . The ConSurf scores were mapped onto the B-value column of the CAPN5-PC crystal structure and visualized using PyMOL.
Circular dichroism analysis
Circular dichroism (CD) spectra were collected using a Jasco J-815 spectrometer in the 200-280 nm range with a 1 mm Spectrosil (Starna) quartz cuvette at 25 C, with a data interval of 0.1 nm and scan speed of 100 nm/min. Purified CAPN5-PC samples (wild-type and p.G267S) were dialyzed against 10 mM Na 2 PO 4 (pH 7.5) and diluted to a concentration of 0.5 -0.7 mg/mL. Ten measurements for each sample were averaged and normalized for total protein concentration after buffer subtraction.
Differential scanning fluorimetry
Purified CAPN5-PC samples (1 mg/mL) were analyzed by differential scanning fluorimetry (DSF) to test the ability of added calcium to bind and alter its thermal stability. Assays were performed on a Bio-Rad CFX96 Touch Thermal Cycler-CFX real-time-PCR system using the FRET channel and contained 300 mM NaCl, 20 mM HEPES (pH 7.5), 2 mM DTT, 5% glycerol, and 5x SYPRO-Orange dye (Invitrogen). Temperature was increased from 1 C /min from 4 C to 100 C in the presence of increasing concentrations of added CaCl 2 (0.5 to 100 mM). As the temperature rose, the protein unfolded to expose hydrophobic residues to the SYPRO-Orange dye, leading to an increase in fluorescence signal. The temperature at which the protein starts to unfold is called the melting temperature (T melt ). Fluorescence traces were analyzed with DMAN software (Wang et al., 2012) .
Intrinsic tryptophan fluorescence measurements
Intrinsic tryptophan fluorescence measurements were performed on a fluorimetric plate reader (Tecan Spark, Mä nnedorf Switzerland) at 22 C in a final volume of 100 mL, in 20 mM Tris-HCl (pH 7.5), 300 mM NaCl, 2 mM DTT, and 1 mM CAPN5-PC with 5 mM EDTA or CaCl 2 (0.1 mM to 100 mM). Excitation and emission wavelengths were set to 280 nm and 340 nm, respectively. Fluorescence intensities (I 340 ) were normalized and fit to the Hill equation.
SAXS data collection and analysis
Purified CAPN5-PC samples were thoroughly dialyzed against 20 mM Tris (pH 7.5), 150 mM NaCl, 5 mM DTT with either 5 mM EDTA or 10 mM CaCl 2 . SAXS data were collected on the 4-2 beamline at the Stanford Synchrotron Radiation Lightsource (SSRL), SLAC National Accelerator Laboratory. Scattering was measured by a Pilatus3 1M (Dectris) hybrid pixel array detector coaxial with the incident beam (Table S2 ). The SAXS data were collected (at 10 C) at three concentrations (0.3, 0.6, 1.2 mg/mL) in the order of lowest to highest concentration with 1 s exposures for 20 s resulting in 20 frames per concentration. Scattering data were reduced using Sas-Tool and beamline scripts. The data from frames before radiation damage occurred were averaged. Scattering curves of the dialysate buffer were collected and subtracted from each protein scattering profile. To assess aggregation or interparticle interference, samples were assessed by analyzing the Guinier region (low-q region) of the scattering data using AutoRg and related programs from the ATSAS Program package (Konarev et al., 2006) . Interparticle interference was observed at the highest concentration. Therefore, the curves from the lowest two concentrations (where Guinier regions were equivalent) were merged to give a single scattering profile for Ca 2+ -free and Ca 2+ -bound CAPN5-PC. The forward scattering I(0) and radius of gyration R g were determined from Guinier approximation. The full scattering curves were estimated using the indirect Fourier transform method implemented in the program DATGNOM, along with the pair distribution function P(r), the maximum dimension of the macromolecule (D max ), and the real space radius of gyration. The Porod volume was determined using the Porod invariant in PRIMUS and GNOM. Dimensionless Kratky analysis was used to determine the folded nature of CAPN5-PC samples in solution. Representative Kratky plots for partially-folded (unbound lysine riboswitch; 3LYSRR) and fully-unfolded protein (red; unfolded lysine riboswitch in Mg 2+ free buffer; 2LYSRR) were used as reference (Garst et al., 2008) . Simulated scattering curves were generated for the CAPN5-PC crystal structure using CRYSOL (Svergun et al., 1995) .
Measurement of calpain activity
Calpain proteolytic activity was measured by hydrolysis of the synthetic calpain substrates, sLY-AMC (N-succinyl-Leu-Tyr-7-amido-4-methylcoumarin; Cayman) and Ac-LLY-AFC (Ac-Leu-Leu-Tyr-7-amino-4-trifluoromethylcoumarin; Fisher) (Wert et al., 2015).
Briefly, 10 mM or 0.25 mM of purified calpain was added to a reaction buffer containing 20 mM Tris-HCl (pH 7.5), 300 mM NaCl, 2 mM DTT, and 0.1 to 100 mM CaCl 2 or 5 mM EDTA and incubated on ice prior to reaction in 96-well plates (100 mL per reaction). Varying concentrations of substrate (10 mM to 1 mM) were added and the reaction was incubated at 37 C for 1 hour on a fluorimetric plate reader (Tecan Spark, Mä nnedorf Switzerland). All experiments were performed in triplicate. The amount of AMC or AFC released during the experiment was calculated based on a standard curve of AMC or AFC concentrations (from 2 nM to 5 mM) and kinetic parameters were calculated by direct fitting to the Michaelis-Menten equation in GraphPad Prism 8. Inhibition experiments were carried out in similar manner with either E-64 (trans-epoxysuccinyl-L-leucylamido-(4-guanidino)-butane (Sigma) or the human CAST B27 domain (residues 184-210; Calbiochem) in the presence of 0.2 mM Ac-LLY-AFC. Reaction rates at various inhibitor concentrations (10 nM to 10 mM) were normalized and fit to the Hill equation in GraphPad Prism 8.
Structure-based phylogenetic analysis of calpain protease core domains Calpain protease core structures were evaluated by their reported global validation metrics in PDB-REDO (R free , Clashscore, Ramachandran outliers, Sidechain outliers, and RSRZ outliers) (Gore et al., 2017; Joosten et al., 2009) . Structures meeting at least 3 out of the 5 metrics, with percentile scores greater than X-ray structures of a similar resolution, were further evaluated. Structures not meeting these criteria were excluded (PDB: 1DF0, 1QXP; 1KFX, 1KFU, and 1U5I). Structures of individual calpain domains (PC1 and PC2) were superimposed using PyMOL to calculate the pairwise RMSD between protein alpha carbon atoms (Ca; The PyMOL Molecular Graphics System, Version 1.8 Schrö dinger, LLC). A structural dissimilarity matrix (SDM) was constructed using the Ca RMSD values in order to generate a phylogenetic tree. The phylogenetic tree was constructed using the UPGMA (Unweighted Pair Group Method with Arithmetic Mean) method in MEGA7 (Molecular Evolutionary Genetics Analysis) software (Kumar et al., 2016; Sneath and Sokal, 1973) . Figure 3A : Intrinsic fluorescence intensity at varying Ca 2+ concentrations. Data were fit to the Hill equation in GraphPad Prism 8 (R 2 = 0.75) and displayed as mean ± SEM (n = 3; number of reactions). Figure 3B : The linear portion of the Guinier region of the SAXS data (such that q x R g < 1.
QUANTIFICATION AND STATISTICAL ANALYSIS
3) is displayed in the inset. Data were fit to a linear regression in GraphPad Prism 8 (R 2 = 0.95 and 0.93 for Ca 2+ -free and Ca 2+ -bound CAPN5-PC, respectively) and represent merged scattering curves from the lowest two concentrations (where Guinier regions were equivalent). Figure 3D : Fit of the theoretical scattering patterns (calculated from the CAPN5-PC structure) to the experimental scattering data. The goodness of fit (c 2 ) was calculated in CRYSOL. c 2 = 1.55 and 8.58 for Ca 2+ -free and Ca 2+ -bound CAPN5-PC, respectively. Figure 3F : Kinetic analysis of sLY-AMC hydrolysis by wild-type CAPN5-PC. Data were fit to the Michaelis-Menten equation in GraphPad Prism 8 (R 2 = 0.96) and displayed as mean ± SEM (n = 3; number of reactions). Figure 3G : Kinetic analysis of CAPN5-PC as a function of increasing Ca 2+ concentrations. Data were fit to the Substrate-Inhibition equation in GraphPad Prism 8 (R 2 = 0.96) and displayed as mean ± SEM (n = 3; number of reactions). The inset represents CAPN5-PC activity at micromolar Ca 2+ levels. Data were fit to the Hill equation (R 2 = 0.97) and displayed as mean ± SEM (n = 3; number of reactions). Figure 3H : Inhibition of CAPN5-PC activity by E-64 and hCAST-B27. Reaction rates were normalized to fractional activity and fit to the Hill equation in GraphPad Prism 8 (R 2 = 0.98 and 0.94 for E-64 and hCAST-B27, respectively). Data are displayed as mean ± SEM (n = 3; number of reactions). Figure 6I : Kinetic analysis of sLY-AMC hydrolysis by wild-type and p.G267S CAPN5-PC. Data were fit to the Michaelis-Menten equation in GraphPad Prism 8 (R 2 = 0.96 and 0.96 for wild-type and p.G267S, respectively) and displayed as mean ± SEM (n = 3; number of reactions). Figure S4B : The melting temperature (T melt ) of CAPN5-PC as a function of increasing Ca 2+ concentrations. Data were fit to the Hill equation GraphPad Prism 8 (R 2 = 0.96) and are displayed as mean ± SD (n = 3; number of reactions). Table S2 . CAPN5-PC SAXS data collection and scattering derived parameters. Related to Figure 3 . Table S3 . Reported kinetic constants for sLY-AMC hydrolysis by calpain proteolytic cores. Related to Figure 3 . 
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